Target

Strategy

References

IGF-I

AS & TH vectors, experimental therapy

Ly et al. (2001) Mol Pathol 54:230

IGF-I-R

AS oligodeoxynucleotide, clinical trial

Andrews et al. (2001) J Clin Oncol 19:2189

c-myb

AS oligodeoxynucleotide, experimental therapy

Hu et al. (2001) Hua XI Yi 32:562

VEGF

AS vector, experimental therapy

Zhang et al. (2002) Zhonghua Yi 80:386

EGF-R

AS vector, experimental therapy

Zhang et al. (2002) J Gene Med 4:183

c-myb

AS oligodeoxynucleotide, experimental therapy

Zhao et al. (2002) Hua XI Yi 33:19

IGF-I

AS & TH vectors, clinical trial

Trojan et al. (2003) Roc Akad Med Biol 48:18

Bcl-2

AS oligodeoxynucleotide, experimental therapy

Zhu et al. (2003) J Neurosci Res 74:60

Laminin-8

AS oligodeoxynucleotide, experimental therapy

Khazenzon et al. (2003) Mol Cancer Ther 2:985

Urokinase plasmin activator

AS vector, experimental therapy

Gondi et al. (2003) Oncogene 22:5967

TGF-beta, FGF and VEGF

AS oligodeoxynucleotide and vector, exp.

therapy

Matsumo & Nagashima (2004) Med Electron Microsc 37:158

AKT2

AS vector, experimental therapy

Pu et al. (2004) Tumor Biol 25:172

TGF-beta2

AS oligodeoxynucleotide (AP 12009), exp. therapy

Schligensiepen et al. (2005) Oligonucleotides 15:94

PKC-alpha

AS oligodeoxynucleotide (aprinocarsen),

clinical trial

Grossman et al. (2005) Neurol Oncol 7:32

TGF-beta2

AS oligodeoxynucleotide (AP 12009), exp. ther., clin. trial

Schlingensiepen et al. (2006) Cytok Growth Factor Rev 17:129

Laminin-8

AS oligodeoxynucleotide, experimental therapy

Fujita et al. (2006) Angiogenesis 9(4):183

FAC (focal adhesive kinase)

AS oligodeoxynucleotide, experimental therapy

Wu et al. (2006) J Neuro Oncol 27(2):117

Galactosyl-

transferase (4GalTV)

AS vector, experimental therapy

Jiang et al. (2006) Glycobiol 16(11):1045

PI3K regulated-ILK

AS oligodeoxynucleotide, experimental therapy

Edwards et al. (2006) Mol Cancer Ther 5(3):645

AKT2

AS vector, experimental therapy

Pu et al. (2006) J Neuro Oncol 76(1):1

VEGF

AS oligodeoxynucleotide, experimental therapy

Hong et al. (2006) Cancer Letters 2361:39

EGF-R

AS vector, experimental therapy

Kang et al. (2006) Cancer Gene Ther 13:530

EGF-R and PTEN

AS vector, experimental therapy

Tian et al. (2006) Neuropath 26(3):178

cMET (receptor tyrosine kinase)

AS oligodeoxynucleotide, experimental therapy

Chou et al. (2006) Surg Neuro 65(6):533

TGF beta 2

AS vector, clinical trial

Fakhrai et al. (2006) Cancer Gene Ther 13:1052

IGF-I

AS & TH vectors, clinical trial

Kasprzak et al. (2006) Neurol Neurochir 40(6):509

IGF-I

AS & TH vectors, clinical trial

Trojan et al. (2007) Int J Cancer Prev 2(4):227

IGF-I, IGF-I-R

AS &TH vectors, experimental therapy and

clinical trial

Trojan et al. (2007) Neuroscience 145:795

TGF-beta 2

AS oligodeoxynucleotide (AP 12009) clinical trial

Hau et al. (2007) Oligonucleotides 17(2):201

Glycogen synthase (GS)

AS vector, experimental therapy

Ardourel et al. (2007) Cancer Biol Ther 6(5):719

Telomerase (hTERT)

AS adenoviruse, experimental therapy

You et al. (2007) Cell Mol Life Sci 64(5):621

Telomerase

AS oligonucleotide (2-5A-anti-hTR), exp. therapy

Iwado et al. (2007) Int J Oncol 31(5):1087

XIAP (inhibitor

of apoptosis)

AS adenovirus, experimental therapy

Naumann et al. (2007) Gene Ther 14(2):147

c-Met (receptor

tyrosin kinase)

AS oligonucleotide, experimental therapy

Chu et al. (2007) J Surg Res 141(2):284

Urokinase (uPAR)

AS vector, experimental therapy

Nabothula et al. (2007) Int J Oncol 30(3):669